Record mula sa primary source
Surrozen dosed the first patient in the open-label Phase 1b single-ascending-dose portion of the DUET study of SZN-8141 in DME patients. The company is expanding the randomized Phase 2a portion from ~60 to 150 patients to evaluate two dose levels versus Vabysmo in treatment-naive and experienced patients. Topline data from Phase 1b is now expected in H2 2027 and Phase 2a in 2028.
EX-99.1 2 srzn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update First patient dosed in Phase 1b of DUET study evaluating SZN-8141 in patients with diabetic macular edema DUET Phase 2a enrollment to be expanded from approximately 60 to 150 patients to enable a more robust evaluation of SZN-8141 in DME Topline data from DUET Phase 1b expected in second half of 2027; Phase 2a topline data expected in 2028 Second tranche of March 2025 PIPE and ATM transaction totaling approximately $118.9 million in net proceeds in October 2026 extend anticipated cash runway into 2029 SOUTH SAN FRANCISCO, Calif., November 09, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company
Isinara ni Surrozen ang $95.1M na Tranche ng Private Placement Pagkatapos ng IND Clearance para sa SZN-8141
Natanggap ng Surrozen ang Clearance ng FDA IND para sa SZN-8141 sa DME